3-oxo-3-(pyrazolidin-1-yl)propionic acid ethyl ester | 852164-78-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-oxo-3-(pyrazolidin-1-yl)propionic acid ethyl ester
• 英文别名: 3-Oxo-3-pyrazolidin-1-yl propionic acid ethyl ester；ethyl 3-oxo-3-pyrazolidin-1-ylpropanoate
• CAS: 852164-78-4
• 化学式: C₈H₁₄N₂O₃
• 分子量: 186.211
• InChiKey: NTXBEJWKMPXLHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-oxo-3-(pyrazolidin-1-yl)propionic acid ethyl ester 、 2-甲硫基-4-嘧啶甲酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 碳酸氢钠 作用下， 以 DMF (N,N-dimethyl-formamide) 、 四氢呋喃 、 水 为溶剂， 反应 22.0h， 生成 3-[2-(2-methylsulfanyl-pyrimidine-4-carbonyl)-pyrazolidin-1-yl]-3-oxo-propionic acid ethyl ester
  参考文献：
  名称：

  Bicyclic pyrazolone cytokine inhibitors

  摘要：

  本发明涉及抑制炎症细胞因子的胞外释放的6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮，该细胞因子负责一个或多个人类或更高级哺乳动物疾病状态。本发明还涉及包含上述6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮的组合物以及预防、减轻或以其他方式控制被认为是负责所述疾病状态的活性成分的酶的方法。

  公开号：

  US20050113392A1
• 作为产物：
  描述：

  2-(2-ethoxycarbonyl-acetyl)-pyrazolidine-1-carboxylic acid benzyl ester 在 palladium on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 生成 3-oxo-3-(pyrazolidin-1-yl)propionic acid ethyl ester
  参考文献：
  名称：

  Bicyclic pyrazolone cytokine inhibitors

  摘要：

  本发明涉及抑制炎症细胞因子的胞外释放的6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮，该细胞因子负责一个或多个人类或更高级哺乳动物疾病状态。本发明还涉及包含上述6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮的组合物以及预防、减轻或以其他方式控制被认为是负责所述疾病状态的活性成分的酶的方法。

  公开号：

  US20050113392A1

文献信息

• Facile Scalable Reduction of <i>N</i>-Acylated Dihydropyrazoles
  作者：Michael D. Curtis、Nancy C. Hayes、Patricia A. Matson

  DOI：10.1021/jo060567j

  日期：2006.6.1

  The reduction of a variety of highly functionalized N-acylated dihydropyrazoles (1) with BH3, pyridine is described. The process through which this unexpectedly difficult reduction was discovered and developed is reported. A facile atom-efficient route to the N-acylated dihydropyrazole reduction precursors (1) is also illustrated. The resulting acylpyrazolidine products (2) that arise upon reduction were isolated in good to high yields following exposure to reaction conditions which have been shown to tolerate a variety of different functional groups. Finally, this route has been demonstrated on a kilogram scale and provides direct access to potential proline surrogates for peptidomimetic applications.
• BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1682551A2

  公开（公告）日：2006-07-26
• US7482356B2
  申请人：——

  公开号：US7482356B2

  公开（公告）日：2009-01-27
• [EN] BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS<br/>[FR] INHIBITEURS DE CYTOKINES A BASE DE PYRAZOLONES BICYCLIQUES
  申请人：PROCTER & GAMBLE

  公开号：WO2005047287A2

  公开（公告）日：2005-05-26

  The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.
• Bicyclic pyrazolone cytokine inhibitors
  申请人：Clark Philip Michael

  公开号：US20050113392A1

  公开（公告）日：2005-05-26

  The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2a]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

  本发明涉及抑制炎症细胞因子的胞外释放的6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮，该细胞因子负责一个或多个人类或更高级哺乳动物疾病状态。本发明还涉及包含上述6,7-二氢-5H-吡唑并[1,2a]吡唑-1-酮的组合物以及预防、减轻或以其他方式控制被认为是负责所述疾病状态的活性成分的酶的方法。